ES2153964T3 - Liberacion controlada de farmacos administrados por via sublingual o bucal. - Google Patents

Liberacion controlada de farmacos administrados por via sublingual o bucal.

Info

Publication number
ES2153964T3
ES2153964T3 ES96919399T ES96919399T ES2153964T3 ES 2153964 T3 ES2153964 T3 ES 2153964T3 ES 96919399 T ES96919399 T ES 96919399T ES 96919399 T ES96919399 T ES 96919399T ES 2153964 T3 ES2153964 T3 ES 2153964T3
Authority
ES
Spain
Prior art keywords
sublingual
oral
road
controlled release
drugs administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919399T
Other languages
English (en)
Spanish (es)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Emad Eldin Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2153964T3 publication Critical patent/ES2153964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES96919399T 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal. Expired - Lifetime ES2153964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/489,966 US5624677A (en) 1995-06-13 1995-06-13 Controlled release of drugs delivered by sublingual or buccal administration

Publications (1)

Publication Number Publication Date
ES2153964T3 true ES2153964T3 (es) 2001-03-16

Family

ID=23946020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919399T Expired - Lifetime ES2153964T3 (es) 1995-06-13 1996-06-13 Liberacion controlada de farmacos administrados por via sublingual o bucal.

Country Status (10)

Country Link
US (1) US5624677A (de)
EP (1) EP0833619B1 (de)
AT (1) ATE198269T1 (de)
AU (1) AU705488B2 (de)
DE (1) DE69611369T2 (de)
DK (1) DK0833619T3 (de)
ES (1) ES2153964T3 (de)
GR (1) GR3035548T3 (de)
PT (1) PT833619E (de)
WO (1) WO1996041619A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
WO1999042466A2 (en) 1998-02-19 1999-08-26 Washington University β-LACTAM-LIKE CHAPERONE INHIBITORS
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
EP1171134A4 (de) * 1999-03-16 2005-01-05 Pentech Pharmaceuticals Inc Gesteuerte freisetznug von sublingual oder bukkal verabreichten sildenafil
EP1671628B1 (de) * 1999-09-03 2012-10-03 APBI Holdings, LLC Selektive Serotonin-Aufnahme Inhibitoren mit schnellem Wirkungseintritt zur Behandlung von sexueller Dysfunktionen
US6841559B1 (en) 1999-11-19 2005-01-11 Washington University Of St. Louis Pyridinones to treat and prevent bacterial infections
MXPA02009904A (es) 2000-04-07 2004-09-06 Tap Pharmaceutical Prod Inc Derivados de apomorfina y metodos para su uso.
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1365740A1 (de) * 2001-02-08 2003-12-03 Pharmacia Corporation Arzneizmittel mit schnellem wirkungseintritt zur behandlung von sexuellen dysfunktion
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
WO2003066029A2 (en) * 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
WO2005102330A2 (en) * 2004-04-16 2005-11-03 Washingtion University Amino methylated 2-pyridinones
MX2007002783A (es) * 2004-09-09 2009-02-12 Bayer Animal Health Gmbh Composición farmacéutica.
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
CA2643924A1 (en) * 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
EP2700638A1 (de) 2006-05-31 2014-02-26 The Regents Of the University of California Purinanaloga
BRPI0719123A2 (pt) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
CA2663280A1 (en) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
WO2008043183A1 (en) * 2006-10-13 2008-04-17 Neuromed Pharmaceuticals Ltd. Cyclopropyl-piperazine compounds as calcium channel blockers
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
US20080318938A1 (en) * 2007-06-22 2008-12-25 Ryckman David M Methods for treating aberrant cell proliferation disorders
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
US7910600B2 (en) * 2007-08-31 2011-03-22 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
US8486928B2 (en) 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
US20090155392A1 (en) * 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
CA2722704A1 (en) * 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
WO2009132454A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
US20090270338A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Diaryl-cyclylalkyl derivatives as calcium channel blockers
CN102014632B (zh) * 2008-04-29 2014-05-28 焦阳特制药股份有限公司 吲哚啉抗癌剂
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
ES2699077T3 (es) 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
US20110065698A1 (en) 2009-08-26 2011-03-17 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US20120003298A1 (en) 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
KR20140003380A (ko) 2010-07-13 2014-01-09 울트라제닉스 파마수티컬 인코포레이티드 시알산 결함 치료용 방법들 및 제형들
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
US20140031302A1 (en) 2010-10-22 2014-01-30 Universite De Strasbourg Pochoxime conjugates useful for the treatment of hsp90 related pathologies
PT2651357T (pt) 2010-12-16 2020-06-17 Sunovion Pharmaceuticals Inc Películas sublinguais
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
CN103582645B (zh) 2011-04-22 2016-02-24 焦阳特制药股份有限公司 二氢氧茚吲哚类似物
HK1201067A1 (en) 2011-10-24 2015-08-21 罕见病药物研发公司 Sialic acid analogs
AU2013327241A1 (en) 2012-10-01 2015-02-26 Urogen Pharma Ltd. Phospholipid drug analogs
US20140335139A1 (en) 2013-05-13 2014-11-13 NeuOra Microceuticals, LLC Long lasting breath mint
KR20160108828A (ko) 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP6847848B2 (ja) 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP3247378B8 (de) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Makrozyklische verbindungen mit beteiligung an einer kooperativen bindung und medizinische verwendungen davon
EP4578461A3 (de) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Verfahren zur behandlung von morbus parkinson durch verabreichung von apomorphin an die mundschleimhaut
US10385085B2 (en) 2015-09-14 2019-08-20 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
EP4242304A3 (de) 2015-10-01 2024-02-07 Revolution Medicines, Inc. Verfahren und reagenzien zur analyse von protein-protein-schnittstellen
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
WO2017187183A1 (en) 2016-04-27 2017-11-02 Itara Therapeutics Methods for the identification of bifunctional compounds
KR20180132939A (ko) 2016-05-03 2018-12-12 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018112061A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
EP3600324A4 (de) 2017-03-23 2020-12-09 Graybug Vision, Inc. Arzneimittel und zusammensetzungen zur behandlung von augenkrankheiten
EP3601286A4 (de) 2017-03-28 2020-09-23 Pimera, Inc. Neue kristalline formen eines pol1-inhibitors
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
US20200308144A1 (en) 2017-12-20 2020-10-01 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
EP3829577A4 (de) * 2018-07-27 2022-12-21 Serina Therapeutics, Inc. Spaltbare konjugate von catecholverbindungen und wasserlöslichen polymeren sowie behandlungsverfahren damit
EP3996746A4 (de) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. Formulierungen von calciumkanalmodulatoren vom t-typ und verwendungsverfahren dafür
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
IL322454A (en) 2019-11-04 2025-09-01 Revolution Medicines Inc ras inhibitors
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
EP4065231A1 (de) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN120659773A (zh) 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2024186579A1 (en) 2023-03-03 2024-09-12 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof
EP4676601A1 (de) 2023-03-03 2026-01-14 Deliver Therapeutics, Inc. Proteinkinasehemmer und verwendungen davon
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025213065A1 (en) 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates
WO2025213185A1 (en) 2024-04-05 2025-10-09 Revolution Medicines, Inc. Peptide conjugates
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
DE3338978A1 (de) * 1982-10-29 1984-05-03 Basf Ag, 6700 Ludwigshafen Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
WO1995028930A1 (en) * 1994-04-22 1995-11-02 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction

Also Published As

Publication number Publication date
US5624677A (en) 1997-04-29
DK0833619T3 (da) 2001-01-22
EP0833619A4 (de) 1998-12-30
EP0833619A1 (de) 1998-04-08
ATE198269T1 (de) 2001-01-15
AU705488B2 (en) 1999-05-20
WO1996041619A1 (en) 1996-12-27
GR3035548T3 (en) 2001-06-29
EP0833619B1 (de) 2000-12-27
DE69611369D1 (de) 2001-02-01
DE69611369T2 (de) 2001-04-26
AU6174996A (en) 1997-01-09
PT833619E (pt) 2001-04-30

Similar Documents

Publication Publication Date Title
ES2153964T3 (es) Liberacion controlada de farmacos administrados por via sublingual o bucal.
TW430562B (en) Controlled release of drugs delivered by sublingual or buccal administration
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
BR9916835A (pt) Composição de galantamina de liberação controlada
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
SE9704546D0 (sv) Novel compounds
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DK0717041T3 (da) Krystallinske paclitaxel-hydrater
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
BR0212931A (pt) Composição farmacêutica de liberação prolongada contendo metformina
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BRPI0412239A (pt) sistemas emulsificantes contendo derivados de azetidina
AP2001002369A0 (en) Pharmaceutical complex.
DE69802943D1 (de) Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut
PT1052995E (pt) Composicao farmaceutica para a administracao por via nasal de tiocolchicosido
UY26746A1 (es) Liberación controlada de fármacos administrados por via sublingual o bucal
AR023056A1 (es) Composiciones farmaceuticas basadas en alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833619

Country of ref document: ES